Celyad Signs Deal With Japan's Ono For CAR-T-Like Program

 
• By Sukaina Virji

Celyad has struck a deal with Ono Pharmaceutical for certain rights to its allogeneic NKR-2 T-cell immunotherapy, a variation on traditional CAR-T approaches. The agreement eases some of the pressure from the recent late stage failure of Celyad's heart failure cell therapy.

Celyad SA of Belgium has signed an exclusive license agreement with Ono Pharmaceutical Co. Ltd. of Japan for the development and commercialization of Celyad's allogeneic NKR-2 T-cell immunotherapy in Japan, Korea and Taiwan.

Celyad will receive an upfront payment of JPY1.25bn ($12.5m) and is eligible for up to JPY30bn ($299m) in development and commercial milestones. Celyad will also receive double digit royalties on...

More from Business

More from Scrip